Your browser doesn't support javascript.
loading
Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 739-742, 2021.
Article in Chinese | WPRIM | ID: wpr-922241
ABSTRACT
45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy.
.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Quinolines / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / ErbB Receptors / Adenocarcinoma of Lung / Indoles / Lung Neoplasms / Mutation Limits: Aged / Aged80 / Female / Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Quinolines / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / ErbB Receptors / Adenocarcinoma of Lung / Indoles / Lung Neoplasms / Mutation Limits: Aged / Aged80 / Female / Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2021 Type: Article